Effectiveness of the XBB.1.5 COVID-19 Vaccines Against
SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During
the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study,
Europe, November 2023 to May 2024

J 2025

Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024

ANTUNES, Liliana; Madelyn ROJAS-CASTRO; Marcos LOZANO; Ivan MARTINEZ-BAZ; Isabel LEROUX-ROELS et. al.

Basic information

Original name

Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024

Authors

ANTUNES, Liliana; Madelyn ROJAS-CASTRO; Marcos LOZANO; Ivan MARTINEZ-BAZ; Isabel LEROUX-ROELS; Maria-Louise BORG; Beatrix OROSZI; Margaret FITZGERALD; Ralf DUERRWALD; Ligita JANCORIENE; Ausenda MACHADO; Goranka PETROVIC; Mihaela LAZAR; Lenka SOUČKOVÁ (203 Czech Republic, belonging to the institution); Sabrina BACCI; Jennifer HOWARD; Nuno VERDASCA; Luca BASILE; Jesus CASTILLA; Silke TERNEST; Ausra DZIUGYTE; Gergo TURI; Roisin DUFFY; Carolin HACKMANN; Monika KULIESE; Veronica GOMEZ; Zvjezdana Lovric MAKARIC; Alexandru MARIN; Petr HUSA (203 Czech Republic, belonging to the institution); Nathalie NICOLAY; Angela M C ROSE and VEBIS SARI VE network TEAM

Edition

Influenza and Other Respiratory Viruses, Hoboken, Wiley, 2025, 1750-2640

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30303 Infectious Diseases

Country of publisher

United States of America

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Impact factor

Impact factor: 4.200 in 2024

Organization unit

Faculty of Medicine

DOI

https://doi.org/10.1111/irv.70081

UT WoS

001439980000001

EID Scopus

2-s2.0-105000000594

Keywords in English

case-control study; elderly; severe acute respiratory infections (SARI); test-negative design; vaccine effectiveness

Abstract

In the original language

We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (>= 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.

Cite

ANTUNES, Liliana; Madelyn ROJAS-CASTRO; Marcos LOZANO; Ivan MARTINEZ-BAZ; Isabel LEROUX-ROELS; Maria-Louise BORG; Beatrix OROSZI; Margaret FITZGERALD; Ralf DUERRWALD; Ligita JANCORIENE; Ausenda MACHADO; Goranka PETROVIC; Mihaela LAZAR; Lenka SOUČKOVÁ; Sabrina BACCI; Jennifer HOWARD; Nuno VERDASCA; Luca BASILE; Jesus CASTILLA; Silke TERNEST; Ausra DZIUGYTE; Gergo TURI; Roisin DUFFY; Carolin HACKMANN; Monika KULIESE; Veronica GOMEZ; Zvjezdana Lovric MAKARIC; Alexandru MARIN; Petr HUSA; Nathalie NICOLAY; Angela M C ROSE and VEBIS SARI VE network TEAM. Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024. Influenza and Other Respiratory Viruses. Hoboken: Wiley, 2025, vol. 19, No 3, p. 1-7. ISSN 1750-2640. Available from: https://doi.org/10.1111/irv.70081.

@article{2488660,
   author = {Antunes, Liliana and RojasandCastro, Madelyn and Lozano, Marcos and MartinezandBaz, Ivan and LerouxandRoels, Isabel and Borg, MariaandLouise and Oroszi, Beatrix and Fitzgerald, Margaret and Duerrwald, Ralf and Jancoriene, Ligita and Machado, Ausenda and Petrovic, Goranka and Lazar, Mihaela and Součková, Lenka and Bacci, Sabrina and Howard, Jennifer and Verdasca, Nuno and Basile, Luca and Castilla, Jesus and Ternest, Silke and Dziugyte, Ausra and Turi, Gergo and Duffy, Roisin and Hackmann, Carolin and Kuliese, Monika and Gomez, Veronica and Makaric, Zvjezdana Lovric and Marin, Alexandru and Husa, Petr and Nicolay, Nathalie and Rose, Angela M C and team, VEBIS SARI VE network},
   article_location = {Hoboken},
   article_number = {3},
   doi = {https://doi.org/10.1111/irv.70081},
   keywords = {case-control study; elderly; severe acute respiratory infections (SARI); test-negative design; vaccine effectiveness},
   language = {eng},
   issn = {1750-2640},
   journal = {Influenza and Other Respiratory Viruses},
   title = {Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024},
   url = {https://onlinelibrary.wiley.com/doi/10.1111/irv.70081},
   volume = {19},
   year = {2025}
}

TY  - JOUR
ID  - 2488660
AU  - Antunes, Liliana - Rojas-Castro, Madelyn - Lozano, Marcos - Martinez-Baz, Ivan - Leroux-Roels, Isabel - Borg, Maria-Louise - Oroszi, Beatrix - Fitzgerald, Margaret - Duerrwald, Ralf - Jancoriene, Ligita - Machado, Ausenda - Petrovic, Goranka - Lazar, Mihaela - Součková, Lenka - Bacci, Sabrina - Howard, Jennifer - Verdasca, Nuno - Basile, Luca - Castilla, Jesus - Ternest, Silke - Dziugyte, Ausra - Turi, Gergo - Duffy, Roisin - Hackmann, Carolin - Kuliese, Monika - Gomez, Veronica - Makaric, Zvjezdana Lovric - Marin, Alexandru - Husa, Petr - Nicolay, Nathalie - Rose, Angela M C - team, VEBIS SARI VE network
PY  - 2025
TI  - Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024
JF  - Influenza and Other Respiratory Viruses
VL  - 19
IS  - 3
SP  - 1-7
EP  - 1-7
PB  - Wiley
SN  - 17502640
KW  - case-control study
KW  - elderly
KW  - severe acute respiratory infections (SARI)
KW  - test-negative design
KW  - vaccine effectiveness
UR  - https://onlinelibrary.wiley.com/doi/10.1111/irv.70081
N2  - We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (>= 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.
ER  -

ANTUNES, Liliana; Madelyn ROJAS-CASTRO; Marcos LOZANO; Ivan MARTINEZ-BAZ; Isabel LEROUX-ROELS; Maria-Louise BORG; Beatrix OROSZI; Margaret FITZGERALD; Ralf DUERRWALD; Ligita JANCORIENE; Ausenda MACHADO; Goranka PETROVIC; Mihaela LAZAR; Lenka SOUČKOVÁ; Sabrina BACCI; Jennifer HOWARD; Nuno VERDASCA; Luca BASILE; Jesus CASTILLA; Silke TERNEST; Ausra DZIUGYTE; Gergo TURI; Roisin DUFFY; Carolin HACKMANN; Monika KULIESE; Veronica GOMEZ; Zvjezdana Lovric MAKARIC; Alexandru MARIN; Petr HUSA; Nathalie NICOLAY; Angela M C ROSE and VEBIS SARI VE network TEAM. Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024. \textit{Influenza and Other Respiratory Viruses}. Hoboken: Wiley, 2025, vol.~19, No~3, p.~1-7. ISSN~1750-2640. Available from: https://doi.org/10.1111/irv.70081.

Přehled o publikaci